Skip to content
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
featured-image

Press Release

The Innovator in AI Enhanced Stroke Imaging Officially Becomes RapidAI

RapidAI acquires comprehensive aneurysm management innovator and expands scope to include aneurysm, extending its leadership in cerebrovascular imaging Menlo Park, Calif. — June 9, 2020 — RapidAI, the worldwide leader in advanced imaging for stroke, today announced the acquisition of EndoVantage, developer of the Find, Track and Treat™ comprehensive cerebral aneurysm management platform. A major neurological condition, it is estimated that 1 in 50 people in the U.S. has an unruptured cerebral aneurysm, with one rupturing and resulting in a brain hemorrhage every 18 minutes. With this news, RapidAI continues to expand its scope, from ischemic stroke to hemorrhagic stroke and now aneurysm. In 2019, RapidAI introduced Rapid ICH, the next step in AI-powered imaging technology for hemorrhages. Now with the acquisition of EndoVantage, the company will also add a concentration on aneurysm. Started at Mayo Clinic and Arizona State University, EndoVantage has developed a powerful award-winning computational platform that provides comprehensive cerebral aneurysm management, automating the entire workflow from initial assessment, growth monitoring, to treatment planning. It utilizes CTA and MRA scans to deliver results that help physicians find and track aneurysm progression, and leverages data from 3D rotational angiograms to deliver detailed 3D models of a patient’s vasculature and allow presurgical planning for the repair of the aneurysm. “By adding the incredible technology developed by EndoVantage to the Rapid platform, we strengthen our position as the global leader in cerebrovascular imaging,” said Don Listwin, CEO of RapidAI. “We can offer hospitals a complete portfolio of products—encompassing ischemic stroke, hemorrhagic stroke, and aneurysm—providing an end-to-end solution that will drive better patient outcomes across the spectrum of cerebrovascular disorders.” “We are very excited to join the Rapid platform of technology. EndoVantage covers the spectrum of cerebral aneurysm care from diagnosis through treatment, which helps physicians decide how best to treat their patients,” said Brian Chong MD, cofounder, EndoVantage. "Each patient’s aneurysm is unique, like the patient. Our technology augments a physician’s clinical acumen and experience helping them determine the best plan for each patient.” The complete Rapid® platform currently includes: Rapid ICH : automatically triages non-contrast CT scans to quickly identify brain hemorrhages with a sensitivity of 95% and specificity 94%* Rapid ASPECTS **: automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury Rapid CTA : automatically assesses regions of reduced blood flow to identify, locate, and alert stroke teams to the presence of large vessel occlusions (LVOs)**. Rapid CTP : fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time Rapid MRI : fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival Rapid Mobile App : securely view Rapid results from multiple sites with customizable notifications on mobile devices *Excluding hemorrhagic transformations (HTs). **Rapid ASPECTS and LVO detection and localization are not commercially available in the U.S.
featured-image

Press Release

RapidAI Introduces Technology Partner Program to Bring RapidAI Technology to more Hospital Environments

Leading Medical Technology and Communications Companies Join the RapidAI Technology Partner Program Menlo Park, Calif. —February 18, 2020 –RapidAI, the worldwide leader in advanced imaging for stroke, today announced the launch of the RapidAI Technology Partner Program, an ecosystem of technologies that complement or integrate with the Rapid platform. In tandem, the company also released a new RapidAI API (Application Programming Interface) to enable technology partners to integrate Rapid results into their products and services. As part of the mission to deliver the benefits of its products to more patients globally and meet each customer’s unique requirements, RapidAI now partners with companies to bring RapidAI technology to more hospital environments through the RapidAI Technology Partner Program. The program is designed to ensure product compatibility and provide a path for healthcare solution providers to integrate and deliver advanced Rapid results through their products. The RapidAI Technology Partner Program broadens the availability of RapidAI technology in more settings, including Mobile Stroke Units (MSUs) and the Angio Suite. It also expands access to Rapid results through more healthcare communication platforms, and increases the options for deployment and implementation of the Rapid platform—on premise or in the cloud. Today, RapidAI is also launching the RapidAI API, which is designed to integrate Rapid notifications and results into a portfolio of workflow and medical communication applications used by healthcare providers to coordinate stroke care for optimal patient outcomes. The RapidAI Technology Partner Program members include Allm, Ambra Health, Halo Communications, Mobile Heartbeat, Pulsara, Samsung Neurologica, Siemens Healthineers, Spok, and TigerConnect. “It is great to see so many leaders in medical technology, workflow, and communications commit to bringing RapidAI technology to more hospital environments and help stroke teams achieve better patient outcomes.” said Don Listwin, CEO of RapidAI. “Every hospital is unique, and in a commitment to delivering Rapid their way, this is yet another path to provide more customer choice.” Partner Quotes “RapidAI’s technology and Allm’s Join app based communications have become a critical and integrated part of stroke care in the U.S. and around the world. Through the RapidAI Technology Partner Program we are helping improve access to life-saving information and results while also speeding the time to care through better communication.” -- Harry Reddy, President of Allm North America We are thrilled to be a RapidAI technology partner. We believe that our solutions partnered together can offer clinicians the resources they need to make critical decisions when time is of the essence." -- Andrew Duckworth, VP of Business Development, Ambra Health “Halo is excited to partner with RapidAI. Halo, together with the Rapid advanced cerebrovascular imaging platform, will help ensure accurate and time-sensitive patient information is communicated to appropriate clinicians. When it comes to treating stroke victims, time is of the essence, and between Halo’s robust clinical communication platform and the RapidAI technology the right teams and individuals can be quickly mobilized to produce better patient outcomes.” -- Angel Mena, M.D., Chief Medical Officer, Halo Communications “We are excited to partner with RapidAI and integrate their advanced neuroimaging platform into the MH-CURE platform via our CURE Connect APIs and the RapidAI API. By leveraging our respective technologies, we can provide a powerful tool to our mutual customers in their drive to save patients afflicted with stroke.” -- Mike Detjen, COO at Mobile Heartbeat “AI is quickly becoming an integral part of all medical imaging offerings. Here at NeuroLogica our mission is to provide more than just imaging equipment, it's to provide health care solutions. Partnerships with companies like RapidAI are essential in accomplishing that mission.” -- David Webster, COO at Neurologica “Siemens Healthineers is proud to work together with RapidAI on exciting new innovations in stroke imaging and care. We embrace the power of this partnership to support our One Stop Stroke initiative.” -- Philip Stenner, Global Head of Marketing Interventional Radiology, Siemens Healthineers “Spok is pleased to be a part of the RapidAI Technology Partner Program. Through our partnership with RapidAI, Spok Go® will automate the delivery of critical stroke results, activating the responsible care team across the hospital network. Together, RapidAI and Spok Go will enable care teams in the 2,200+ hospitals that Spok serves to receive critical results on their preferred devices, improving care team collaboration, expediting time to treatment, and helping drive better patient outcomes.” -- Dave Nuthals, VP Product Strategy, Spok
featured-image

Press Release

Press Release: The Innovator in AI Enhanced Stroke Imaging Officially Becomes RapidAI

The company that pioneered the usage of artificial intelligence (AI) in advanced imaging for stroke, embraces AI leadership with a new brand. Menlo Park, Calif. —February 18, 2020 – iSchemaView, also known as RAPID, the worldwide leader in advanced imaging for stroke, today announced the company is now RapidAI. In 2018, co-founder Dr. Greg Albers presented groundbreaking findings at the International Stroke Conference (ISC) that supported expanded treatment window guidelines for stroke patients. Based on intelligence gained from over 650,000 scans across more than 1,500 hospitals in over 50 countries, the AI-enhanced Rapid platform has become the gold standard for advanced imaging for stroke. Now on the heels of unprecedented worldwide usage and availability of the Rapid platform, RapidAI is unveiling new branding, a new website, and technology partner news at ISC 2020 (Booth #315). RapidAI News from ISC 2020 at the Los Angeles Convention Center, Feb 18-21 RAPID becomes RapidAI. The company that leads AI-enhanced stroke imaging around the globe, embraces the future with a new brand and website, RapidAI.com . RapidAI Launches Technology Partner Program. The RapidAI Technology Partner Program gives customers the flexibility to deploy the Rapid platform and access Rapid results according to their organization’s needs. The program broadens the availability of RapidAI technology in more environments, including Mobile Stroke Units (MSUs) and Angio Suites. It also expands access to RapidAI results through more healthcare communication platforms, and increases the options for deployment and implementation of the Rapid platform—on premise or in the cloud. RapidAI Product Showcase Highlights at ISC The full Rapid advanced imaging platform which includes Rapid CTP, Rapid MRI, Rapid CTA, Rapid ICH, and Rapid ASPECTS The Rapid Mobile App provides stroke team members fast access to RapidAI results, the ability to preview source files, and communicate about patient care Rapid U, the advanced role-based training and certification program for Rapid products The RapidAI Presentation Theater at the International Stroke Conference 2020 Stop by the RapidAI booth #315. Grab a seat and learn about the latest advancements in comprehensive stroke care from Dr. Greg Albers and other leaders in stroke. The full schedule of sessions can be found at https://www.rapidai.com/isc2020presentationtheater and include: Precision Medicine and the Future of Stroke Care Mobile Stroke Units: Conclusive Field Diagnosis and Improved Patient Routing Case Study: Suffolk County's Mobile Stroke Units Optimizing Workflows for Hyper-Acute Stroke Patients Mobilizing Clinical Communications at Enterprise Scale Case study: Coordinating and Streamlining Acute Stroke Care Communication To learn more visit RapidAI at booth #315, and online at RapidAI.com
featured-image

Press Release

Rapid Celebrates Record-Breaking Year in Stroke Care

Rapid announces record-breaking performance metrics for 2019 Menlo Park, Calif. —January, 23 2020 –RAPID, the worldwide leader in advanced imaging for stroke, today announced record-breaking performance metrics for 2019. Newly released numbers reveal accelerating growth in the number of countries and hospitals where RAPID is available and in use, as well as over 100% growth in the number of scans processed. As RAPID brought AI enhanced stroke imaging to more of the world, the company also launched innovative new imaging products and supported critical new stroke research. The RAPID artificial intelligence framework helps to quantify brain lesions and extends the window of potential stroke intervention from six hours after onset to up to 24 hours, for patients with salvageable brain tissue. RAPID provides physicians with fast, fully automated, and easy-to-interpret imaging that facilitates clinical decision-making around stroke. In 2019, RAPID: Expanded its worldwide footprint to 50 countries, including Vietnam, Israel and Mexico Grew adoption to over 1,500 hospitals, including major networks and systems around the world Processed over 650,000 stroke imaging scans Continued to set the standard in research, surpassing 40 research studies, including a total of 15 multicenter, multinational stroke clinical trials In addition to record-breaking availability, growth and usage, in 2019, RAPID also introduced: RAPID ICH: a fully-automated system that uses the latest in artificial intelligence to quickly triage non-contrast CT (NCCT) cases and notify clinicians of possible intracranial hemorrhage (ICH). RAPID ICH can detect all types of brain hemorrhages with a sensitivity and specificity greater than 90%. RAPID LVO detection and localization: a critical new feature within RAPID CTA that makes it the only advanced imaging product indicated for localization of a detected Large Vessel Occlusion (LVO). RAPID CTA can now detect LVOs with a sensitivity of 95% and specificity of 90%, and immediately notifies a stroke team when an LVO is detected. RAPID CTP enhancements: advanced motion correction, AIF selection improvement and ventricle masking.  RAPID Mobile app enhancements: the leading mobile stroke imaging experience added HIPAA-compliant in-app messaging for more efficient care coordination across stroke teams and sites, real-time message notification as well as capture of clinical data to align stroke teams on key patient information. RAPID U: a new learning system and certification program that sets the international standard for professional status as a RAPID imaging practitioner. Role-based learning modules empower multiple members of stroke care teams to quickly become proficient. RAPID U is a resource-rich learning platform enhanced with videos, case studies, and publications. In 2019, RAPID also introduced innovations in AI-enhanced stroke imaging to enable Mobile Stroke Units (MSU) as well as expanded cloud and on-premise availability, to meet the needs of every hospital and stroke team. “Last year we redoubled our efforts to bring the most advanced AI-enhanced stroke imaging platform to every part of the world, and through innovation and a dedication to our mission, we beat even our most aggressive estimates,” said Don Listwin, CEO of RAPID. “Aside from records in usage and availability, we were able to launch RAPID 5.0, RAPID ICH and RAPID U. 2019 was a gratifying year. We now again commit ourselves to making the best even better, and helping improve stroke outcomes everywhere.” Developed by leading stroke experts, RAPID technology has been selected for use in several ground-breaking trials that have changed treatment guidelines issued by both the American Heart Association and American Stroke Association. The RAPID artificial intelligence framework combines deep learning, machine learning and expert feature extraction. It is the only clinically validated imaging solution for stroke diagnostic support worldwide.
featured-image

Press Release

Rapid Advanced Medical Imaging for Stroke Now Installed in Vietnam

Rapid expands worldwide reach to bring Vietnam the only clinically validated, next generation imaging platform for assessing stroke Menlo Park, Calif. — December 17, 2019 – RAPID, the worldwide leader in advanced imaging for stroke, is now available and installed in Vietnam. The RAPID artificial intelligence framework helps to quantify brain lesions and extend the window of potential stroke intervention from six hours after onset to up to 24 hours, for patients with salvageable brain tissue. RAPID provides physicians with fast, fully automated, and easy-to-interpret imaging that facilitates clinical decision-making around stroke. According to the Vietnam Stroke Association, there are approximately 200,000 new stroke cases every year, 90% of which have long term consequnces and complications. Hospitals and clinics that treat stroke in Vietnam will now have access to the RAPID automated CTP, MRI, CTA, ASPECTS and ICH solutions, as well as their unique mobile app that accelerates the provision of information to support treatment decisionmaking. RAPID’s expansion into Vietnam represents continued market growth across Asia, and is further confirmation that RAPID has become the de facto standard for stoke imaging around the world. "Strokes are a medical emergency, and urgent treatment is essential. However, only about 19% of patients arrive at our hospitals within 4-6 hours after experiencing stroke symptoms,” commented Dr. Thang Huy Nguyen, Senior Stroke Consultant, Head of Department of Cerebrovascular Disease, 115 People's Hospital. “The RAPID technology provides physicians and stroke teams the ability to diagnose more stroke patients by extending the treatment window up to 24 hours. Moving forward our teams will be able to utilize this advanced technology via the RAPID platform to promptly address more cases with the highest efficiency.” Developed by leading stroke experts, RAPID technology has been selected for use in several ground-breaking trials that have changed stroke treatment guidelines issued by both the American Heart Association and American Stroke Association. The RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. It is the only clinically validated imaging solution for stroke diagnostic support worldwide. In 2019, this proven platform is being used for more than 400,000 scans by thousands of healthcare professionals in over 45 countries. The Complete RAPID Platform includes: RAPID CTP: fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time RAPID MRI: fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival RAPID CTA: automatically delivers CT angiography maps and identifies brain regions with reduced blood vessel density in 2D and 3D outputs RAPID ASPECTS: automatically identifies areas of early ischemic change on noncontrast CT scans, which predicts irreversible injury RAPID ICH : automatically triages non-contrast CT scans to quickly identify brain hemorrhages with a sensitivity and specificity >90% RAPID Mobile: securely preview RAPID results from multiple sites with customizable notifications on mobile devices “With RAPID in Vietnam we continue to extend the global footprint to give more hospitals the tools they need to help stroke patients achieve the best possible outcomes and quality of life,” said Anil Singhal, MD, SVP, Worldwide Operations at RAPID. “Vietnamese hospitals are already reporting positive outcomes that may not have been possible prior to RAPID being available. We are very proud to be partnering with these facilities to help provide the best care for their patients.” For more information about working with RAPID in Vietnam and across Asia, contact Alex Oh, VP International Sales for APAC at +1 (949) 232-3365 or Oh@RAPID.ai .
featured-image

Press Release

Rapid Releases New Stroke Imaging Trends For World Stroke Day

Stroke Care and Imaging is Expanding Quickly, Bringing Life-Saving Treatment Opportunities to More People Around the World. In the US, Major Growth is Occurring at Primary Stroke Centers, Indicating Expansion in Rural and Suburban Areas San Francisco, Calif. –October 29, 2019 – To commemorate World Stroke Day, RAPID, the worldwide leader in advanced imaging for stroke, is releasing new global stroke findings. The RAPID platform will process over 400,000 scans this year and has uncovered compelling data around stroke imaging based on the large number of scans processed to date. Findings include triple-digit increases in stroke imaging since new American Heart Association (AHA) and American Stroke Association (ASA) treatment guidelines were established at the beginning of 2018. They also reveal a large expansion in imaging studies performed in suburban and rural areas, as imaging at Primary Stroke Centers (PSC) increased substantially. The RAPID platform is designed to provide physicians with fast, fully automated, and easy-to-interpret imaging that facilitates clinical decision-making around stroke. From 2017 to 2018 there was over a 250% increase in patients imaged with RAPID worldwide. Additionally, RAPID has already imaged over 211,000 patients in the first three quarters of 2019 and identified over 47,000 potential patients for thrombectomies (minimally invasive treatment of stroke), based on imaging criteria. Featured Worldwide Stroke Findings: Since new AHA/ASA stroke guidelines and an extended window of potential treatment went into effect in January 2018, the number of suspected stroke patients undergoing RAPID imaging, at centers live in both 2017 and 2019, has increased by more than 100% worldwide (24,644 in 2017 and 51,261 in just the first 9 months of 2019). This suggests stroke centers have substantially increased the number of patients that undergo advanced imaging and can potentially be treated. There was over a 300% increase in suspected stroke patients scanned since 2018 in Primary Stroke Centers (10,080 in 2018 and 35,517 in the first 9 months of 2019). With most scans traditionally taking place in Comprehensive Stroke Centers (CSC), these data show a large percentage increase in scans that occurred in PSCs. This suggests a movement in initial stroke imaging from specialized centers to primary stroke centers and community hospitals, as well as an expansion of stroke care in suburban and rural areas. In the US, the largest number of scans, based on RAPID data, are being done in the “Stroke Belt” region of the southeast, particularly for patients between 65 and 74 years old. Worldwide, women are undergoing advanced imaging for suspected strokes at a slightly, but consistently higher rate than men, based on RAPID data (211,135 women and 201,425 men in 2019). “This World Stroke Day we can really see in the numbers that AI-enhanced medical imaging, along with newer 24-hour stroke treatment guidelines, are making a substantial difference in stroke care around the globe,” said Don Listwin, CEO of iSchemaView. “Whether it’s more imaging at PSCs or more thrombectomies now indicated, it all supports our goal of better outcomes for more people.” The 2018 American Heart Association and American Stroke Association guidelines have significantly altered and expanded the management of acute stroke. Several of the studies that led to these new guidelines were led by Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and Co-founder of iSchemaView. Please also join Dr. Greg Albers on October 29, 2019, at 3:00pm ET, for a special World Stroke Day Webinar, The Transparent Time Window: A New Perspective on Stroke Treatment.
featured-image

Press Release

Rapid Platform Expands to Address Hemorrhagic Stroke

AI-powered Rapid ICH advanced imaging quickly notifies clinicians of possible intracranial hemorrhage. San Francisco, Calif. – October 21, 2019 – iSchemaView, the worldwide leader in advanced imaging for stroke, today launched the newest addition to the RAPID platform, RAPID ICH1 at the 2019 Congress of Neurological Surgeons (CNS) Annual Meeting. This fully-automated system uses the latest in artificial intelligence to quickly triage non-contrast CT (NCCT) cases and notify clinicians of possible intracranial hemorrhage (ICH). RAPID ICH will enable hospitals and mobile stroke units on the front lines of stroke patient assessment to better streamline treatment decision making. For a demonstration, visit RAPID at CNS Booth #229. RAPID ICH can detect all types of brain hemorrhages with a sensitivity and specificity greater than 90%. This innovative technology was developed and validated using over a thousand CT scans from stroke centers worldwide. This new RAPID module automatically processes images from a scanner and assesses them for hemorrhage. Results are immediately available to doctors via PACS/Workstation, RAPID Mobile app and email. “RAPID ICH is the next step in AI-powered imaging technology,” said Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of iSchemaView. “By providing radiologists, neurologists and other clinicians this level of detection for all types of hemorrhages in such a small window of time, from minutes compared to the current standard of care of more than an hour, will promote better and faster decision making for improved patient care and outcomes. RAPID ICH will be extremely useful to facilitate triage decisions in both primary stroke centers and mobile stroke units.” Developed by leading stroke experts, RAPID technology has been selected for use in several ground-breaking trials that have changed treatment guidelines issued by both the American Heart Association and American Stroke Association. The RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. It is the only clinically validated imaging solution for stroke diagnostic support worldwide. This proven platform is being used for more than 350,000 scans per year by thousands of healthcare professionals in over 40 countries. The Complete RAPID Platform now includes: RAPID CTP: fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time RAPID MRI: fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival RAPID CTA: automatically delivers CT angiography maps and identifies brain regions with reduced blood vessel density in 2D and 3D outputs RAPID ASPECTS: automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury RAPID ICH: automatically triages non-contrast CT scans to quickly identify brain hemorrhages with a sensitivity and specificity >90% RAPID Mobile: securely preview RAPID results from multiple sites with customizable notifications on mobile devices “The innovative technology used in RAPID ICH taps into the latest in artificial intelligence to help clinicians make life saving decisions,” said Don Listwin, CEO of iSchemaView. “RAPID ICH’s highly accurate detection of possible intracranial hemorrhages expands RAPID’s offerings past ischemic events to also include hemorrhagic. In the end, this gives stroke care teams the ability to successfully identify and treat more stroke patients than ever before.”
featured-image

Press Release

Rapid receives registration approval in Japan

Rapid is now available to hospitals across Japan, helping doctors in that country make smart, fast treatment decisions around stroke. Menlo Park, Calif. — July 8, 2019 – iSchemaView, the worldwide leader in advanced imaging for stroke, has received registration approval under the Japanese Pharmaceutical Affairs Law through third-party review by the Japanese Association for the Advancement of Medical Equipment for its RAPID imaging platform. With this news the technology is available to hospitals across Japan, with the support of Micron, the Japanese RAPID distributor. RAPID is designed to provide physicians with fast, fully automated, and easy-to-interpret imaging that facilitates clinical decision-making around stroke. “Stroke remains the fourth most common cause of death in Japan, and as the population ages, stroke is likely to become an increasing health burden on the country,” said Dr. Manabu Inoue from National Cerebral and Cardiovascular Center. “With RAPID’s AI-powered imaging technology we will be able to better address our patients to provide them with the best routes of care, improving their chances of recovery.” Developed by leading stroke experts, RAPID technology has been selected for use in several ground-breaking trials that have changed treatment guidelines issued by both the American Heart Association and American Stroke Association. The RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. Together these provide unparalleled sensitivity and specificity across stroke modules (CT perfusion, MR diffusion and perfusion, CTA and CT ASPECT scoring). Results are then delivered by the RAPID Intelligence Services Platform via PACS, email, text, the RAPID app or corporate partner workflow systems. The Complete RAPID Platform includes: RAPID CTP: fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time RAPID MRI: fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival RAPID CTA: automatically delivers CT angiography maps and identifies brain regions with reduced blood vessel density in 2D and 3D outputs RAPID ASPECTS: automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury RAPID Mobile App : Securely review RAPID results from multiple sites with customizable notifications “With approval for RAPID in Japan, we extend a global footprint that gives more hospitals the tools they need to help stroke patients achieve the best outcomes and quality of life,” said Anil Singhal, MD, SVP, Worldwide Operations at iSchemaView. “Our goal is to help as many stroke patients as possible by delivering the only clinically validated, next-generation imaging technology available.” For more information about working with RAPID in Japan, contact Alex Oh, VP International Sales for APAC at +1 (949) 232-3365 or Oh@RAPID.ai . About Micron Micron is a Japanese leading imaging CRO and provides clinical trial support services with expertise in medical image handling. Micron offers a wide range of services, including imaging protocol standardization, image analysis, site management, and clinical monitoring to enhance the efficiency, reproducibility, and reliability of clinical trials. The company also engages in the development, sales, and marketing of the imaging analysis software which can be utilized in clinical trials for evaluating the efficacy or safety of drugs and in clinical disease progression. RAPID is one of such software, and was approved as a medical device by Pharmaceutical Affairs Law successfully in a short period of time with the great contribution of Micron. For more information, visit www.micron-kobe.com
featured-image

Press Release

International approval update

Menlo Park, Calif. —June 19, 2019 – International Approval Update: iSchemaView has received representative approval of its official manufacturing representatives from the Kingdom of Saudi Arabia’s Ministry of Health (MOH), for the RAPID imaging platform. RAPID product approval is pending in the Kingdom of Saudi Arabia.
4 5 6 7 8